LANTERN PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.07 USD | -3.65% |
|
-3.19% | +41.82% |
| May. 29 | Transcript : Lantern Pharma Inc. - Special Call | |
| May. 24 | Lantern Pharma Files $150 Million Mixed Shelf | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 119.7 | 89.28 | 65.58 | 46.52 | 65.31 | - | - |
| Enterprise Value (EV) 1 | 119.7 | 89.28 | 65.58 | 46.52 | 65.31 | 65.31 | 65.31 |
| P/E ratio | -14.1 x | -7.06 x | -4.61 x | -2.91 x | -2.64 x | -3.19 x | -4.62 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | 33.5 x |
| EV / Revenue | - | - | - | - | - | - | 33.5 x |
| EV / EBITDA | - | -7,094,197 x | -4,954,807 x | - | - | - | - |
| EV / FCF | - | -8,416,928 x | -5,125,032 x | - | - | - | - |
| FCF Yield | - | -0% | -0% | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 6,218 | 11,188 | 10,857 | 10,869 | 10,759 | - | - |
| Reference price 2 | 19.25 | 7.980 | 6.040 | 4.280 | 6.070 | 6.070 | 6.070 |
| Announcement Date | 3/10/21 | 3/10/22 | 3/20/23 | 3/18/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 1.95 |
| EBITDA | - | -12.58 | -13.23 | - | - | - | - |
| EBIT 1 | -5.908 | -12.59 | -14.43 | -17.88 | -25.37 | -30.74 | -28.49 |
| Operating Margin | - | - | - | - | - | - | -1,461.23% |
| Earnings before Tax (EBT) 1 | -5.908 | -12.36 | -14.26 | -15.96 | -24.8 | -29.46 | -27.89 |
| Net income 1 | -5.908 | -12.36 | -14.26 | -15.96 | -24.8 | -29.67 | -27.89 |
| Net margin | - | - | - | - | - | - | -1,430.46% |
| EPS 2 | -1.370 | -1.130 | -1.310 | -1.470 | -2.295 | -1.900 | -1.315 |
| Free Cash Flow | - | -10.61 | -12.8 | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/10/21 | 3/10/22 | 3/20/23 | 3/18/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | -3.509 | -4.064 | - | -1.841 | -3.493 | -3.949 | -4.794 | - | - | - | - | - | - |
| EBIT 1 | -3.511 | -4.066 | -4.395 | -2.145 | -3.826 | -4.286 | -5.19 | -3.524 | -4.877 | -5.732 | -6.196 | -6.588 | -7.05 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -3.54 | -4.122 | -4.492 | -2.265 | -3.381 | -3.868 | -4.746 | -3.161 | -4.186 | -5.441 | -5.971 | -6.438 | -6.925 |
| Net income 1 | -3.54 | -4.122 | -4.492 | -2.265 | -3.381 | -3.868 | -4.746 | -3.161 | -4.186 | -5.441 | -5.971 | -6.438 | -6.925 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.3100 | -0.3800 | -0.4100 | -0.2100 | -0.3100 | -0.3600 | -0.4400 | -0.2900 | -0.3800 | -0.5100 | -0.5550 | -0.5950 | -0.6400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/10/22 | 5/3/22 | 8/8/22 | 11/7/22 | 3/20/23 | 5/9/23 | 8/9/23 | 11/8/23 | 3/18/24 | 5/9/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -10.6 | -12.8 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | 0.03 | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 3/10/21 | 3/10/22 | 3/20/23 | 3/18/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
6.07
USD
Average target price
22
USD
Spread / Average Target
+262.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +41.82% | 65.31M | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B | |
| -11.83% | 10.74B |
- Stock Market
- Equities
- LTRN Stock
- Financials Lantern Pharma Inc.
